T1	CHEM 82 92	adalimumab
#1	AnnotatorNotes T1	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	DISO 111 130	artritis psoriásica
#2	AnnotatorNotes T2	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T3	PROC 154 220	Estudio multicéntrico, aleatorizado, abierto, con grupos paralelos
T4	CHEM 324 334	adalimumab
#3	AnnotatorNotes T4	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	DISO 353 372	artritis psoriásica
#4	AnnotatorNotes T5	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T6	CHEM 393 466	fármacos antirreumáticos modificadores de la enfermedad de tipo biológico
#5	AnnotatorNotes T6	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T7	DISO 490 500	Enfermedad
#6	AnnotatorNotes T7	C0012634; Disease; Disease or Syndrome
T8	ANAT 538 552	articulaciones
#7	AnnotatorNotes T8	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T9	DISO 580 599	Artritis psoriásica
#8	AnnotatorNotes T9	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T10	CHEM 57 67	ixekizumab
#9	AnnotatorNotes T10	C3489764; ixekizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	DISO 639 658	artritis psoriásica
#10	AnnotatorNotes T11	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T12	PROC 695 706	diagnóstico
#11	AnnotatorNotes T12	C0011900; Diagnosis; Diagnostic Procedure
T13	DISO 776 795	Artritis Psoriásica
#12	AnnotatorNotes T13	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T14	CHEM 302 312	ixekizumab
#13	AnnotatorNotes T14	C3489764; ixekizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	DISO 806 825	Artritis psoriásica
#14	AnnotatorNotes T15	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T16	ANAT 880 894	articulaciones
#15	AnnotatorNotes T16	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T17	DISO 916 940	articulaciones hinchadas
#16	AnnotatorNotes T17	C0152031; Joint swelling; Finding
T18	DISO 956 975	psoriasis en placas
#17	AnnotatorNotes T18	C0263361; Psoriasis vulgaris; Disease or Syndrome
T19	PROC 1031 1052	método anticonceptivo
#18	AnnotatorNotes T19	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T20	CHEM 1149 1164	anticonceptivos
#19	AnnotatorNotes T20	C0009871; Contraceptive Agents; Pharmacologic Substance
T21	PROC 1254 1276	detener el tratamiento
#20	AnnotatorNotes T21	C0850893; stop medication; Therapeutic or Preventive Procedure
T22	CHEM 1327 1345	agentes biológicos
#21	AnnotatorNotes T22	C0005515; Biological Factors; Biologically Active Substance
T23	PROC 1354 1365	tratamiento
#22	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	DISO 1393 1427	síndromes artríticos inflamatorios
T25	DISO 880 902	articulaciones blandas
#23	AnnotatorNotes T25	C0240094; Joint tenderness; Sign or Symptom
T26	DISO 1438 1458	espondiloartropatías
#24	AnnotatorNotes T26	C0949691; Spondylarthropathies; Disease or Syndrome
T27	DISO 1475 1494	Artritis psoriásica
#25	AnnotatorNotes T27	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T28	CHEM 1575 1580	IL-17
T29	DISO 1607 1616	Trastorno
#26	AnnotatorNotes T29	C0012634; Disease; Disease or Syndrome
T30	DISO 1625 1635	enfermedad
#27	AnnotatorNotes T30	C0012634; Disease; Disease or Syndrome
T31	DISO 1657 1666	Infección
#28	AnnotatorNotes T31	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T32	DISO 511 516	dolor
#29	AnnotatorNotes T32	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T33	PROC 260 298	se comparan la eficacia y la seguridad
T34	ANAT 916 930	articulaciones
#30	AnnotatorNotes T34	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T35	CHEM 1594 1604	ixekizumab
#31	AnnotatorNotes T35	C3489764; ixekizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T36	CHEM 1542 1573	antagonistas de interleucina 17
#32	AnnotatorNotes T36	C4318164; Interleukin-17 Receptor A Antagonist; Pharmacologic Substance
T37	DISO 519 552	inflamacion en las articulaciones
#33	AnnotatorNotes T37	C0574941; Inflamed joint; Finding
T38	Date 13 17	2016
T39	LIVB 97 106	pacientes
#34	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	Duration 226 236	52 semanas
T41	LIVB 339 348	pacientes
#35	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Neg_cue 377 379	no
T43	Duration 674 690	al menos 6 meses
T44	Date 729 740	actualmente
T45	LIVB 989 996	hombres
#36	AnnotatorNotes T45	C0025266; Male population group; Population Group
T46	LIVB 1110 1117	mujeres
#37	AnnotatorNotes T46	C0043210; Woman; Population Group
T47	Duration 1219 1242	por lo menos 12 semanas
T48	Date 1308 1314	actual
T49	Duration 1676 1695	los últimos 3 meses
T50	LIVB 1698 1705	Mujeres
#38	AnnotatorNotes T50	C0043210; Woman; Population Group
T51	PHYS 1716 1727	amamantando
#39	AnnotatorNotes T51	C0006147; Breast Feeding; Organism Function
T52	PROC 1073 1084	abstinentes
#40	AnnotatorNotes T52	C2042176; abstinence from sexual contact; Therapeutic or Preventive Procedure
T53	PROC 1186 1197	abstinentes
#41	AnnotatorNotes T53	C2042176; abstinence from sexual contact; Therapeutic or Preventive Procedure
T54	DISO 438 448	enfermedad
#42	AnnotatorNotes T54	C0012634; Disease; Disease or Syndrome
T55	Neg_cue 1459 1471	distintas de
T56	DISO 834 837	PsA
#43	AnnotatorNotes T56	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T57	DISO 1374 1377	PsA
#44	AnnotatorNotes T57	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T58	DISO 1496 1499	PsA
#45	AnnotatorNotes T58	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T59	DISO 1651 1654	PsA
#46	AnnotatorNotes T59	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T60	Neg_cue 1636 1647	distinta de
A1	Assertion T6 Negated
A2	Status T6 History_of
A3	Status T22 History_of
A4	Status T23 History_of
A5	Assertion T27 Negated
A6	Assertion T58 Negated
A7	Assertion T59 Negated
#47	AnnotatorNotes T3	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C1709323; Open Label Study; Research Activity + C2826345; Parallel Study; Research Activity 
#48	AnnotatorNotes T33	C0511730; Identify product efficacy and safety issues; Health Care Activity
#49	AnnotatorNotes T28	C0384648; Interleukin-17; Amino Acid, Peptide, or Protein · Immunologic Factor 
#50	AnnotatorNotes T48	C0521116; Current (present time); Temporal Concept 
#51	AnnotatorNotes T44	C0521116; Current (present time); Temporal Concept 
R1	Experiences Arg1:T39 Arg2:T10	
R2	Experiences Arg1:T39 Arg2:T1	
R3	Experiences Arg1:T39 Arg2:T2	
R4	Has_Duration_or_Interval Arg1:T3 Arg2:T40	
R5	Experiences Arg1:T41 Arg2:T14	
R6	Experiences Arg1:T41 Arg2:T4	
R7	Experiences Arg1:T41 Arg2:T5	
R8	Negation Arg1:T42 Arg2:T6	
R9	Experiences Arg1:T41 Arg2:T6	
R10	Causes Arg1:T7 Arg2:T32	
R11	Causes Arg1:T7 Arg2:T37	
R12	Location_of Arg1:T8 Arg2:T37	
R13	Location_of Arg1:T8 Arg2:T32	
R14	Has_Duration_or_Interval Arg1:T11 Arg2:T43	
T61	Quantifier_or_Qualifier 659 665	activa
#52	AnnotatorNotes T61	C0679217; Active State; Idea or Concept
R15	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T61	
T62	Quantifier_or_Qualifier 707 718	establecido
#53	AnnotatorNotes T62	C0443211; Established; Qualitative Concept
R16	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T62	
T63	CONC 745 795	criterios de Clasificación por Artritis Psoriásica
R17	Used_for Arg1:T63 Arg2:T12	
T64	CONC 797 803	CASPAR
#54	AnnotatorNotes T64	['ClASsification criteria for Psoriatic ARthritis']
R18	Used_for Arg1:T64 Arg2:T12	
R19	Overlap Arg1:T64 Arg2:T44	
R20	Overlap Arg1:T63 Arg2:T44	
T65	Quantifier_or_Qualifier 826 832	activa
#55	AnnotatorNotes T65	C0679217; Active State; Idea or Concept
T66	Quantifier_or_Qualifier 976 982	activa
#56	AnnotatorNotes T66	C0679217; Active State; Idea or Concept
R21	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T66	
R22	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T65	
R23	Has_Quantifier_or_Qualifier Arg1:T56 Arg2:T65	
T67	Quantifier_or_Qualifier 1428 1435	activos
#57	AnnotatorNotes T67	C0679217; Active State; Idea or Concept
R24	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T67	
R25	Negation Arg1:T55 Arg2:T27	
R26	Negation Arg1:T55 Arg2:T58	
R27	Overlap Arg1:T22 Arg2:T48	
R28	Used_for Arg1:T22 Arg2:T23	
T68	Quantifier_or_Qualifier 869 879	al menos 3
R29	Location_of Arg1:T16 Arg2:T25	
R30	Overlap Arg1:T15 Arg2:T25	
R31	Overlap Arg1:T56 Arg2:T25	
R32	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T68	
T69	Quantifier_or_Qualifier 905 915	al menos 3
R33	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T69	
R34	Location_of Arg1:T34 Arg2:T17	
R35	Overlap Arg1:T15 Arg2:T17	
R36	Overlap Arg1:T25 Arg2:T17	
R37	Overlap Arg1:T56 Arg2:T17	
R38	Experiences Arg1:T45 Arg2:T19	
R39	Experiences Arg1:T45 Arg2:T52	
T70	Quantifier_or_Qualifier 1165 1172	fiables
#58	AnnotatorNotes T70	C3858758; Reliable; Functional Concept
R40	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T70	
T71	Quantifier_or_Qualifier 1053 1059	fiable
#59	AnnotatorNotes T71	C3858758; Reliable; Functional Concept
R41	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T71	
T72	PROC 1096 1103	Estudio
#60	AnnotatorNotes T72	C0008976; Clinical Trials; Research Activity
R42	Overlap Arg1:T52 Arg2:T72	
R43	Overlap Arg1:T19 Arg2:T72	
T73	PROC 1209 1216	estudio
#61	AnnotatorNotes T73	C0008976; Clinical Trials; Research Activity
R44	Overlap Arg1:T53 Arg2:T73	
R45	Overlap Arg1:T20 Arg2:T73	
R46	Experiences Arg1:T46 Arg2:T20	
R47	Experiences Arg1:T46 Arg2:T21	
R48	Has_Duration_or_Interval Arg1:T53 Arg2:T47	
R49	After Arg1:T53 Arg2:T21	
T74	Observation 1503 1537	Participación en cualquier estudio
R50	Negation Arg1:T60 Arg2:T59	
T75	Quantifier_or_Qualifier 1617 1622	grave
#62	AnnotatorNotes T75	C1547227; Severe - Severity of Illness Code; Intellectual Product
R51	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T75	
T76	Quantifier_or_Qualifier 1667 1672	grave
#63	AnnotatorNotes T76	C1547227; Severe - Severity of Illness Code; Intellectual Product
R52	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T76	
R53	Overlap Arg1:T31 Arg2:T49	
R54	Experiences Arg1:T50 Arg2:T51	
R55	Experiences Arg1:T41 Arg2:T54	
A8	Experiencer T39 Patient
A9	Experiencer T41 Patient
A10	Experiencer T45 Patient
A11	Experiencer T46 Patient
A12	Experiencer T50 Patient
